Schizophrenia is a devastating disorder that profoundly impairs mental and social functioning, bringing significant consequences not only for those affected but also for their families (Shamsaei et al., 2015; Patel et al., 2014; Shultz et al., 2007; van Os & Kapur, 2009). In the United States, approximately 1 in 100 people are affected by schizophrenia, representing over $340 billion in societal costs as of 2019 (McGrath et al., 2008; Shultz & Murray, 2016; Kadakia et al., 2022). The impacts are not only felt by those diagnosed but ripple through families and communities.
Advances in psychiatric therapeutics over the last 30 years have led to improvements in psychotic symptoms, social functioning, and quality of life.
The Overlooked Aspects: Negative Symptoms and Cognitive Impairment
Less well-known, however, is that individuals with schizophrenia often also suffer from negative symptoms (blunted affect, poverty of speech, and social withdrawal) and cognitive impairment (Jackson et al., 2017; Shultz & Murray, 2016; Bowie & Harvey, 2006; Correll & Schooler, 2020; Harvey & Strassing, 2012; Tripathi et al., 2018; Velligan et al., 2010). These symptoms can be as debilitating as the more widely recognized positive symptoms, significantly impairing the individual’s ability to engage in everyday activities and maintain social relationships. Despite their severe impact, negative symptoms and cognitive impairments have historically received less attention from researchers and clinicians. This oversight is partly due to the complexity of these symptoms and the lack of effective treatments available. For many years, treatment efforts have primarily focused on alleviating positive symptoms, leading to a gap in comprehensive care for individuals with schizophrenia. However, recent advancements in understanding these symptoms and developing targeted therapies are beginning to address this critical need.
Emerging Treatments and Digital Therapeutics
From a treatment development perspective, there is renewed hope for individuals with schizophrenia and their families. New prescription digital therapeutics—software applications often available through smartphones—are either currently available or under development. These digital tools are designed to deliver cognitive behavioral therapy, aiming to treat cognitive impairments and negative symptoms such as social withdrawal, blunted affect, and poverty of speech. By offering these therapies through accessible platforms like smartphones, patients can receive consistent, personalized support in real-time, complementing traditional treatment methods. These advancements not only promise to enhance symptom management but also aim to improve overall quality of life and social functioning for individuals with schizophrenia. As these technologies continue to evolve, they hold the potential to revolutionize the way schizophrenia is treated, making comprehensive care more attainable and effective for those in need.
The Need for Real-World Evidence (RWE) & Generating Innovative Approaches
To fully realize the potential of these novel therapeutics, more real-world evidence (RWE) is needed. This evidence will help healthcare providers, payors, and patients understand the value of new treatments targeting negative symptoms and cognitive impairments in schizophrenia. However, developing RWE in this area is challenging due to limitations in traditional datasets, such as insurance claims, which are based on the current standard for diagnostic codes—the International Classification of Diseases version 10 (ICD-10). ICD-10 does not include specific codes for negative symptoms or cognitive impairments related to schizophrenia, making it difficult to accurately capture and analyze these aspects of the disorder. As a result, alternative methods for generating RWE are needed. These might include patient and provider surveys, as well as the analysis of clinical progress notes from electronic health records. By employing these innovative approaches, researchers can gather comprehensive data that reflects the real-world impact of new therapies, thereby supporting their adoption and integration into standard care practices.
The journey towards comprehensive treatment for schizophrenia is ongoing. With the continued development of novel therapeutics and the advancement of digital health solutions, there is a promising future for those affected by this disorder. By focusing on both positive and negative symptoms and leveraging innovative research methodologies, we can enhance the quality of life for individuals with schizophrenia and their families.